| Title: |
Autoantibodies, antigen-autoantibody complexes and antigens complement CA125 for early detection of ovarian cancer |
| Authors: |
Young Han, Chae; Bedia, Jacob S.; Yang, Wei-Lei; Hawley, Sarah J.; Bergan, Lindsay; Hopper, Marika; Celestino, Joseph; Guo, Jing; Gornet, Terrie G.; Soosaipillai, Antoninus; Yang, Hailing; Doskocil, Samantha D.; Lokshin, Anna E.; Handy, Beverly C.; Diamandis, Eleftherios P.; Moore, Richard G.; Lu, Karen H.; Lu, Zhen; Anderson, Karen S.; Drescher, Charles W.; Skates, Steven J.; Bast, Robert C. |
| Contributors: |
Division of Cancer Prevention, National Cancer Institute; Cancer Prevention and Research Institute of Texas |
| Source: |
British Journal of Cancer ; volume 130, issue 5, page 861-868 ; ISSN 0007-0920 1532-1827 |
| Publisher Information: |
Springer Science and Business Media LLC |
| Publication Year: |
2024 |
| Description: |
Background Multiple antigens, autoantibodies (AAb), and antigen-autoantibody (Ag-AAb) complexes were compared for their ability to complement CA125 for early detection of ovarian cancer. Methods Twenty six biomarkers were measured in a single panel of sera from women with early stage (I-II) ovarian cancers ( n = 64), late stage (III-IV) ovarian cancers (186), benign pelvic masses (200) and from healthy controls (502), and then split randomly (50:50) into a training set to identify the most promising classifier and a validation set to compare its performance to CA125 alone. Results Eight biomarkers detected ≥ 8% of early stage cases at 98% specificity. A four-biomarker panel including CA125, HE4, HE4 Ag-AAb and osteopontin detected 75% of early stage cancers in the validation set from among healthy controls compared to 62% with CA125 alone ( p = 0.003) at 98% specificity. The same panel increased sensitivity for distinguishing early-stage ovarian cancers from benign pelvic masses by 25% ( p = 0.0004) at 95% specificity. From 21 autoantibody candidates, 3 AAb (anti-p53, anti-CTAG1 and annt-Il-8) detected 22% of early stage ovarian cancers, potentially lengthening lead time prior to diagnosis. Conclusion A four biomarker panel achieved greater sensitivity at the same specificity for early detection of ovarian cancer than CA125 alone. |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| DOI: |
10.1038/s41416-023-02560-z |
| Availability: |
https://doi.org/10.1038/s41416-023-02560-z; https://www.nature.com/articles/s41416-023-02560-z.pdf; https://www.nature.com/articles/s41416-023-02560-z |
| Rights: |
https://creativecommons.org/licenses/by/4.0 ; https://creativecommons.org/licenses/by/4.0 |
| Accession Number: |
edsbas.9DC8BD |
| Database: |
BASE |